Get the Stockscreener App
59.12
1.38%
-0.83
After Hours:
59.20
0.08
+0.14%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $59.12, with a volume of 11.42M.
It is down -1.38% in the last 24 hours and up +4.51% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$59.95
Open:
$58.87
24h Volume:
11.42M
Relative Volume:
1.11
Market Cap:
$119.91B
Revenue:
$47.44B
Net Income/Loss:
$-7.26B
P/E Ratio:
-16.47
EPS:
-3.59
Net Cash Flow:
$13.80B
1W Performance:
+0.61%
1M Performance:
+4.51%
6M Performance:
+21.22%
1Y Performance:
+21.37%
1-Day Range:
$58.73
$59.85
1-Week Range:
$58.55
$60.31
52-Week Range:
$39.35
$61.10
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.12 | 119.91B | 47.44B | -7.26B | 13.80B | -3.59 |
|
LLY
Lilly Eli Co
|
826.07 | 785.10B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
82.62 | 366.80B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
153.49 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
189.95 | 335.67B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
90.74 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol-Myers Squibb's SWOT analysis: stock outlook mixed amid pipeline progress - MSN
Cantor Fitzgerald lifts Bristol-Myers price target to $55 - Investing.com
Greenwood Capital Associates LLC Sells 4,698 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen And Bristol Myers Squibb - Barchart
The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb - Yahoo Finance
4,335 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Synergy Asset Management LLC - MarketBeat
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi - Yahoo Finance
What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 Earnings - MSN
Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘With That Yield, It’s One Of My Faves’ - Insider Monkey
Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings? - Yahoo Finance
KG&L Capital Management LLC Sells 15,435 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Jennison Associates LLC - MarketBeat
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - The Motley Fool
FSM Wealth Advisors LLC Buys New Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
McAdam LLC Acquires 4,426 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Greenleaf Trust - MarketBeat
Milestone Asset Management LLC Purchases New Shares in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Gries Financial LLC - MarketBeat
Manning & Napier Advisors LLC Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Inlet Private Wealth LLC Cuts Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Valley National Advisers Inc. Raises Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
CENTRAL TRUST Co Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Position Increased by Concord Wealth Partners - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Osborne Partners Capital Management LLC - MarketBeat
Sivik Global Healthcare LLC Invests $3.96 Million in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Caprock Group LLC Has $4.44 Million Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Cibc World Market Inc. Decreases Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol-Myers Squibb Company (BMY) Is Among the Best Long Term Low Risk Stocks to Buy Now - Insider Monkey
BMS receives positive CHMP opinion for Opdivo plus Yervoy as a first-line treatment option for advanced hepatocellular carcinoma - Indian Pharma Post
Bristol-Myers Squibb (BMY) Expected to Announce Earnings on Thursday - MarketBeat
Buffington Mohr McNeal Acquires New Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Decreased by Robeco Institutional Asset Management B.V. - MarketBeat
YHB Investment Advisors Inc. Reduces Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $65.00 at Citigroup - MarketBeat
Perigon Wealth Management LLC Boosts Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
BankPlus Wealth Management LLC Makes New $521,000 Investment in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts - Benzinga
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma - BioSpace
EMA panel backs Bristol Myers' Opdivo-Yervoy for liver cancer - Investing.com
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma - Business Wire
Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain - Seeking Alpha
Sumitomo Life Insurance Co. Reduces Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Foster & Motley Inc. Increases Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
New England Research & Management Inc. Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Asset Dedication LLC Has $819,000 Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Nilsine Partners LLC Invests $357,000 in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb's SWOT analysis: stock faces challenges amid growth prospects - MSN
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):